UK Markets close in 8 hrs 19 mins
  • FTSE 100

    0.00 (0.00%)
  • FTSE 250

    0.00 (0.00%)
  • AIM

    0.00 (0.00%)

    -0.0004 (-0.04%)

    -0.0032 (-0.2484%)

    +23.52 (+0.23%)
  • CMC Crypto 200

    +0.77 (+0.29%)
  • S&P 500

    +11.90 (+0.34%)
  • DOW

    -28.13 (-0.10%)

    -1.33 (-3.34%)

    -4.20 (-0.22%)
  • NIKKEI 225

    -22.25 (-0.09%)

    +132.68 (+0.54%)
  • DAX

    0.00 (0.00%)
  • CAC 40

    +58.26 (+1.20%)

Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen

Eurobio Scientific
·3-min read

Eurobio Scientific launches a first rapid diagnostic test
for the detection of the SARS CoV-2 virus antigen

Paris, September 22, 2020 –6:00 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life sciences, today announces the launch of a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen . This test, Sofia® SARS Antigen developed by its American partner Quidel, is complementary to PCR tests which remain the performance gold standard in terms of detection of the virus responsible for COVID-19. It is already CE marked and immediately available for sale.

As part of the current campaign to detect the presence of the SARS CoV-2 virus in patients, the number of tests performed in France has become of such magnitude (more than 1 million tests per week) that the delays in submitting results have lengthened considerably.
Even if their virus detection performance is lower than that of PCR tests, rapid antigenic tests make it possible to carry out a rapid initial screening of asymptomatic patients. Such a process would unclog testing laboratories while maintaining the scale of the viral activity monitoring campaign.

With a catalog of products among the most complete on the market, with PCR tests, including its proprietary tests EBX 041 and FluCoSyn, as well as several serological tests, Eurobio Scientific is now completing its offer for the detection of SARS CoV-2, aware of the public health and economic stake that the current wave of the COVID-19 epidemic can represent.

Immunofluorescence-based unit test

For many years, Eurobio Scientific has been ensuring the exclusive distribution in France of the Sofia® range from Quidel. This new unit test which allows the detection of the SARS-Cov-2 antigen completes this range which already includes, among others, the antigenic detection tests for Influenza A and B. It requires a nasal swab sample, and a Sofia® reader, which uses FIA (Fluorescence ImmunoAssay) technology to deliver a result in 15 minutes.

These instruments are already widely available to Eurobio Scientific customers, with more than 350 readers mainly used for rapid diagnosis in hospitals across France.

For Jean-Michel Carle, Chairman and CEO of Eurobio Scientific, “It was particularly important for our group to complete its range of screening tests in order to meet the demands of our customers. The overcrowding of analytical laboratories required an evolution in the testing technologies that we immediately make available to them. Our offer now includes a first test already CE marked and intended for our customers equipped with the Sofia® reader, mainly hospital departments requiring rapid unit tests. "

Next financial meeting
Half-year 2020 financial results : October 15, 2020, after stock market closes

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

For more information, please visit :

The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP


Group Eurobio Scientific
Denis Fortier, General Manager
Hervé Duchesne de Lamotte, General Manager
Tel. +33(0) 1 69 79 64 80

Mathieu Calleux / Gregory Bosson
Investors relations
Tel. +33(1) 53 65 68 68